UY37576A - Anticuerpos dirigidos a hueso - Google Patents

Anticuerpos dirigidos a hueso

Info

Publication number
UY37576A
UY37576A UY0001037576A UY37576A UY37576A UY 37576 A UY37576 A UY 37576A UY 0001037576 A UY0001037576 A UY 0001037576A UY 37576 A UY37576 A UY 37576A UY 37576 A UY37576 A UY 37576A
Authority
UY
Uruguay
Prior art keywords
antibodies
directed antibodies
bone
fragments
bone directed
Prior art date
Application number
UY0001037576A
Other languages
English (en)
Inventor
James Stefano
Sunghae Park
Huawei Qiu
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of UY37576A publication Critical patent/UY37576A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Se proporcionan anticuerpos recombinantes y conjugados químicamente y fragmentos de los mismos modificados con uno o más péptidos de poli-aspartato (poli-D) (p.ej., una secuencia D10) para mejorar la localización de los anticuerpos o fragmentos en el hueso. También se describen los métodos para elaborar y utilizar estos anticuerpos y fragmentos.
UY0001037576A 2017-01-20 2018-01-19 Anticuerpos dirigidos a hueso UY37576A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762448763P 2017-01-20 2017-01-20

Publications (1)

Publication Number Publication Date
UY37576A true UY37576A (es) 2018-10-31

Family

ID=61581744

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037576A UY37576A (es) 2017-01-20 2018-01-19 Anticuerpos dirigidos a hueso

Country Status (17)

Country Link
US (2) US10844115B2 (es)
EP (1) EP3571226A2 (es)
JP (2) JP7227138B2 (es)
KR (2) KR20230172039A (es)
CN (1) CN111032690B (es)
AR (1) AR110755A1 (es)
AU (1) AU2018210270A1 (es)
BR (1) BR112019013986A2 (es)
CA (1) CA3050884A1 (es)
IL (1) IL268114A (es)
MX (2) MX2019008549A (es)
MY (1) MY194819A (es)
SG (1) SG11201906663VA (es)
TW (2) TWI788321B (es)
UY (1) UY37576A (es)
WO (1) WO2018136698A2 (es)
ZA (1) ZA201907673B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190216943A1 (en) * 2016-08-11 2019-07-18 Precithera, Inc. Tgf-beta antagonist conjugates
JP2024517212A (ja) 2021-05-07 2024-04-19 ベイラー カレッジ オブ メディスン 中等症から重症の骨形成不全症の処置
WO2023004348A1 (en) * 2021-07-20 2023-01-26 William Marsh Rice University Engineered compositions for bone-targeted therapy
CA3237245A1 (en) 2021-11-01 2023-05-04 Genzyme Corporation Treatment of osteogenesis imperfecta

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
SI9720020B (en) 1996-02-09 2001-12-31 Basf Ag Human antibodies that bind human TNF alpha
WO1998035703A2 (en) 1997-02-14 1998-08-20 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
EP1585771A4 (en) 2002-12-31 2006-11-29 Altus Pharmaceuticals Inc COMPLEXES OF PROTEIN CRYSTALS AND IONIC POLYMERS
US20060286105A1 (en) 2003-04-30 2006-12-21 Steven Ledbetter Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
HUE039448T2 (hu) 2004-04-21 2018-12-28 Alexion Pharma Inc Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására
ES2711213T3 (es) 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
SG10201605629VA (en) 2008-01-03 2016-08-30 Scripps Research Inst Antibody targeting through a modular recognition domain
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
CN102325795B (zh) 2008-12-22 2015-03-25 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂的抗体
JP2012524818A (ja) 2009-04-24 2012-10-18 バンダービルト ユニバーシティ 骨細胞機能および骨成長の抗ＴＧＦ−βによる誘導法
IL300733A (en) 2010-03-05 2023-04-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeting immune modulation
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
KR102051014B1 (ko) 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
JP6180408B2 (ja) 2011-06-13 2017-08-16 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
WO2013058833A1 (en) 2011-10-19 2013-04-25 Enobia Canada Limited Partnership Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) * 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
MX361773B (es) 2012-05-31 2018-12-17 Innate Pharma Agentes de ligación a tlr3.
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014062978A1 (en) 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
ES2700238T5 (es) * 2013-03-20 2022-05-20 Genzyme Corp Métodos para tratar la osteogénesis imperfecta
EP3816625A1 (en) 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions and methods for growth factor modulation
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015140150A1 (en) 2014-03-17 2015-09-24 Piotr Jachimczak Combination for use in a method of treating cancer
US20180265874A1 (en) 2014-10-10 2018-09-20 Global Biopharma, Inc. Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
HUE050894T2 (hu) 2015-04-17 2021-01-28 Bristol Myers Squibb Co Kompozíciók, amelyek tartalmazzák ipilimumab és nivolumab kombinációját
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
CA2996996A1 (en) * 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
US20190216943A1 (en) 2016-08-11 2019-07-18 Precithera, Inc. Tgf-beta antagonist conjugates

Also Published As

Publication number Publication date
WO2018136698A3 (en) 2018-08-30
JP7227138B2 (ja) 2023-02-21
KR102613463B1 (ko) 2023-12-15
US20210163584A1 (en) 2021-06-03
AR110755A1 (es) 2019-05-02
CN111032690B (zh) 2024-03-26
WO2018136698A2 (en) 2018-07-26
MX2019008549A (es) 2019-09-11
US20180208650A1 (en) 2018-07-26
MX2022008073A (es) 2022-07-27
TW202330597A (zh) 2023-08-01
RU2019126026A3 (es) 2021-11-09
US10844115B2 (en) 2020-11-24
BR112019013986A2 (pt) 2020-03-03
AU2018210270A1 (en) 2019-09-05
EP3571226A2 (en) 2019-11-27
IL268114A (en) 2019-09-26
CN111032690A (zh) 2020-04-17
TWI788321B (zh) 2023-01-01
JP2020505919A (ja) 2020-02-27
MY194819A (en) 2022-12-17
CA3050884A1 (en) 2018-07-26
ZA201907673B (en) 2021-05-26
TW201839013A (zh) 2018-11-01
JP2023058590A (ja) 2023-04-25
RU2019126026A (ru) 2021-02-20
KR20190105236A (ko) 2019-09-16
SG11201906663VA (en) 2019-08-27
KR20230172039A (ko) 2023-12-21
TWI832600B (zh) 2024-02-11

Similar Documents

Publication Publication Date Title
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
UY37576A (es) Anticuerpos dirigidos a hueso
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
ECSP18082207A (es) Neoantígenos y métodos de su uso
AR121749A2 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
IL281192A (en) Interleukin-2 polypeptide conjugates and uses thereof
CO2019010503A2 (es) Plataforma de identificación de péptidos inmunogénicos personalizada
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
BR112019012343A2 (pt) anticorpos il-11ra
EA201792245A1 (ru) Биоконъюгаты и их применения
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
PH12021551136A1 (en) ENGINEERED ROBUST HIGH Tm-PHYTASE CLADE POLYPEPTIDES AND FRAGMENTS THEREOF
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
PH12016502535A1 (en) Interferon alpha and omega antibody antagonists
CL2017003228A1 (es) Fragmentos mutantes de proteína ras
CY1123738T1 (el) Προσδετες που ενισχυουν τη βιοδραστικοτητα των γοναδοτροπινων
CO2017011964A2 (es) Un metodo para producir hcg recombinante
PE20200487A1 (es) Proteinas de union al antigeno anti-jagged1
IL268971B1 (en) A polypeptide, a segment of a polypeptide, its derivation and their applications
MX2020006758A (es) Cemento de alumina.
AU2017305946A8 (en) C1q and HMGB1 fusion proteins and uses thereof
IL277632A (en) CDNF fragments from the carboxyl end, pharmaceutical compositions containing them and their uses
MX2022014899A (es) Variantes y composiciones del lfa3 y sus usos.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231026